Wednesday, June 29, 2022

Cannabis Science Inc (OTCMKTS:CBIS) Isn’t Sending the Best Signals

Cannabis Science Inc (OTCMKTS:CBIS) is a penny play in the MMJ space that has been famous for share creation and dilution for a long time. But the company has been vastly improving its messaging over the past several months and has been rewarded by the market despite not managing to actually transition into sales growth. Now, we are seeing more dilution on the way with the company’s announcement that it has selected “an influential Southern California financial firm as the lead to raise the proposed 25 Million USD in expansion capital and boost its industry footprint by pursuing several industry business models on behalf of the Company within the Cannabis Industry.”

“We have been enthusiastically reviewing investment firms that have expressed interest in our business model that have similar humanitarian interests and dedication to the industry, and we didn’t have to look far. We think we certainly found the right group, with the right mindset, and the right track record. We expect to formally announce the Firm once preparations are complete for a formal presentation directly after the Global Health Catalyst (GHC) Summit @ Harvard Medical School,” stated Mr. Raymond C. Dabney, President & CEO, Co-Founder, Cannabis Science Inc.

Cannabis Science Inc (OTCMKTS:CBIS) has been down an interesting road over recent months. We see the company as actively striving for, and achieving a bump in legitimacy through some of its newly established relationships.

The company defines itself according to the narrative of a leading-edge researcher and designer of cannabinoid solutions to health problems.

CBIS is involved in developing medicines for autism, blood pressure, cancer and cancer side effects, as well as for other illnesses comprising for general health maintenance. It also develops CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of available therapies; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a proprietary cannabis-based therapy for neurological conditions.

Cannabis Science Inc also has collaboration with IGXBio, Inc. to develop GenePro, a DNA-based immunotherapeutic drug.

In addition, CBIS offers an online video-based medical cannabis education system, including courses, such as medical cannabis law, medical marijuana, cooking, horticulture, and bud tending; and manufactures and distributes specialty horse and pet grooming and topical applications. It has a license agreement with Apothecary Genetics Investments LLC to produce various brand formulations for California medical cannabis market.

Subscribe below and we’ll keep you on top of what’s happening before $CBIS stock makes its next move.

As noted above, the company has apparently selected its lead in a new capital raise round. We don’t know the specifics, but imagine it will be dilutive. In any case, management will be blowing full volume through the megaphone into the round, a process now underway with the company’s latest press release.

“As a direct result of our CRA with Dana Farber we have experienced a considerable increase in the number of expanded research collaborations requests targeting several ailments from Universities, Foundations, Corporations, and Private Investors. These groups seem to have one thing in common: they are all looking to get involved with our research programs with Dana Farber and beyond. They are looking to target one or more critical ailments of interest to their group or just invest in a study based on their previous life experiences. This is exactly what we were hoping for, expansion through partnerships and acquisitions.

“We have also experienced a very large number of self-medicating patients looking for cannabinoid information or actual new cannabinoid medication they can purchase for their specific condition. This is truly profound, what is happening right now, all around us; once again we are certainly making history with all those working with us, especially Dana Farber. We are certainly blessed and our goal is to pass on our knowledge, medications, and resources to the millions of patients worldwide seeking natural alterative medications for their conditions. The anticipated 25 Million in new funding will certainly allow us to meet this demand while we fast tracking our formal FDA initiatives through Dana Farber and really begin to make a noticeable difference,” stated Mr. Raymond C. Dabney, President & CEO, Co-Founder, Cannabis Science Inc.

At this time, carrying a capital value in the market of $181.9M, CBIS has a chunk ($333K) of cash on the books, which must be weighed relative to about $2M in total current liabilities. CBIS should be seen as having reverted back to a pre-revenue form at this point (or perhaps seen as having nearly -100% sales growth). We will update the story again soon as further details emerge. For continuing coverage on shares of $CBIS stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!

Related Articles


Please enter your comment!
Please enter your name here

Stay Connected


Latest Articles